Tags

Type your tag names separated by a space and hit enter

Increased tissue arachidonic acid and reduced linoleic acid in a mouse model of cystic fibrosis are reversed by supplemental glycerophospholipids enriched in docosahexaenoic acid.
J Nutr. 2009 Dec; 139(12):2358-64.JN

Abstract

An imbalance in (n-6)/(n-3) PUFA has been reported in cystic fibrosis (CF) patients. Glycerophospholipids enriched in docosahexaenoic acid (GPL-DHA) have been shown to regulate the (n-6)/(n-3) fatty acid ratio in the elderly. Here, we tested the effect of GPL-DHA supplementation on PUFA status in F508del homozygous CF mice. GPL-DHA liposomes were administrated by gavage (60 mg DHA/kg daily, i.e. at maximum 1.4 mg DHA/d) to 1.5-mo-old CF mice (CF+DHA) and their corresponding wild-type (WT) homozygous littermates (WT+DHA) for 6 wk. The PUFA status of different tissues was determined by GC and compared with control groups (CF and WT). There was an alteration in the (n-6) PUFA pathway in several CF-target organs in CF compared with WT mice, as evidenced by a higher level of arachidonic acid (AA) in membrane phospholipids or whole tissue (21 and 39% in duodenum-jejunum, 32 and 38% in ileum, and 19 and 43% in pancreas). Elevated AA levels were associated with lower linoleic acid (LA) and higher dihomo-gamma-linolenic acid levels. No DHA deficiency was observed. GPL-DHA treatment resulted in different PUFA composition changes depending on the tissue (increase in LA, decrease in elevated AA, DHA increase, increase in (n-6)/(n-3) fatty acid ratio). However, the DHA/AA ratio consistently increased in all tissues in CF+DHA and WT+DHA mice. Our study demonstrates the effectiveness of an original oral DHA formulation in counter-balancing the abnormal (n-6) fatty acid metabolism in organs of CF mice when administrated at a low dose and highlights the potential of the use of GPL-DHA as nutritherapy for CF patients.

Authors+Show Affiliations

INSERM, U 476 Nutrition Humaine et Lipides, Marseille, France.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19828687

Citation

Mimoun, Myriam, et al. "Increased Tissue Arachidonic Acid and Reduced Linoleic Acid in a Mouse Model of Cystic Fibrosis Are Reversed By Supplemental Glycerophospholipids Enriched in Docosahexaenoic Acid." The Journal of Nutrition, vol. 139, no. 12, 2009, pp. 2358-64.
Mimoun M, Coste TC, Lebacq J, et al. Increased tissue arachidonic acid and reduced linoleic acid in a mouse model of cystic fibrosis are reversed by supplemental glycerophospholipids enriched in docosahexaenoic acid. J Nutr. 2009;139(12):2358-64.
Mimoun, M., Coste, T. C., Lebacq, J., Lebecque, P., Wallemacq, P., Leal, T., & Armand, M. (2009). Increased tissue arachidonic acid and reduced linoleic acid in a mouse model of cystic fibrosis are reversed by supplemental glycerophospholipids enriched in docosahexaenoic acid. The Journal of Nutrition, 139(12), 2358-64. https://doi.org/10.3945/jn.109.110999
Mimoun M, et al. Increased Tissue Arachidonic Acid and Reduced Linoleic Acid in a Mouse Model of Cystic Fibrosis Are Reversed By Supplemental Glycerophospholipids Enriched in Docosahexaenoic Acid. J Nutr. 2009;139(12):2358-64. PubMed PMID: 19828687.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Increased tissue arachidonic acid and reduced linoleic acid in a mouse model of cystic fibrosis are reversed by supplemental glycerophospholipids enriched in docosahexaenoic acid. AU - Mimoun,Myriam, AU - Coste,Thierry C, AU - Lebacq,Jean, AU - Lebecque,Patrick, AU - Wallemacq,Pierre, AU - Leal,Teresinha, AU - Armand,Martine, Y1 - 2009/10/14/ PY - 2009/10/16/entrez PY - 2009/10/16/pubmed PY - 2010/1/7/medline SP - 2358 EP - 64 JF - The Journal of nutrition JO - J. Nutr. VL - 139 IS - 12 N2 - An imbalance in (n-6)/(n-3) PUFA has been reported in cystic fibrosis (CF) patients. Glycerophospholipids enriched in docosahexaenoic acid (GPL-DHA) have been shown to regulate the (n-6)/(n-3) fatty acid ratio in the elderly. Here, we tested the effect of GPL-DHA supplementation on PUFA status in F508del homozygous CF mice. GPL-DHA liposomes were administrated by gavage (60 mg DHA/kg daily, i.e. at maximum 1.4 mg DHA/d) to 1.5-mo-old CF mice (CF+DHA) and their corresponding wild-type (WT) homozygous littermates (WT+DHA) for 6 wk. The PUFA status of different tissues was determined by GC and compared with control groups (CF and WT). There was an alteration in the (n-6) PUFA pathway in several CF-target organs in CF compared with WT mice, as evidenced by a higher level of arachidonic acid (AA) in membrane phospholipids or whole tissue (21 and 39% in duodenum-jejunum, 32 and 38% in ileum, and 19 and 43% in pancreas). Elevated AA levels were associated with lower linoleic acid (LA) and higher dihomo-gamma-linolenic acid levels. No DHA deficiency was observed. GPL-DHA treatment resulted in different PUFA composition changes depending on the tissue (increase in LA, decrease in elevated AA, DHA increase, increase in (n-6)/(n-3) fatty acid ratio). However, the DHA/AA ratio consistently increased in all tissues in CF+DHA and WT+DHA mice. Our study demonstrates the effectiveness of an original oral DHA formulation in counter-balancing the abnormal (n-6) fatty acid metabolism in organs of CF mice when administrated at a low dose and highlights the potential of the use of GPL-DHA as nutritherapy for CF patients. SN - 1541-6100 UR - https://www.unboundmedicine.com/medline/citation/19828687/Increased_tissue_arachidonic_acid_and_reduced_linoleic_acid_in_a_mouse_model_of_cystic_fibrosis_are_reversed_by_supplemental_glycerophospholipids_enriched_in_docosahexaenoic_acid_ L2 - https://academic.oup.com/jn/article-lookup/doi/10.3945/jn.109.110999 DB - PRIME DP - Unbound Medicine ER -